Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)

Purpose The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to dete...

Full description

Saved in:
Bibliographic Details
Main Authors: Ricarda A L Menke, Michael Lawton, Thomas R Barber, Johannes C Klein, Clare Mackay, Konrad Szewczyk-Krolikowski, Michele T Hu, Michal Rolinski, Ludovica Griffanti, Samuel G Evetts, Faye Begeti, Marie Crabbe, Jane Rumbold, Richard Wade-Martins
Format: Article
Language:English
Published: BMJ Publishing Group 2020-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/8/e034110.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846147109665898496
author Ricarda A L Menke
Michael Lawton
Thomas R Barber
Johannes C Klein
Clare Mackay
Konrad Szewczyk-Krolikowski
Michele T Hu
Michal Rolinski
Ludovica Griffanti
Samuel G Evetts
Faye Begeti
Marie Crabbe
Jane Rumbold
Richard Wade-Martins
author_facet Ricarda A L Menke
Michael Lawton
Thomas R Barber
Johannes C Klein
Clare Mackay
Konrad Szewczyk-Krolikowski
Michele T Hu
Michal Rolinski
Ludovica Griffanti
Samuel G Evetts
Faye Begeti
Marie Crabbe
Jane Rumbold
Richard Wade-Martins
author_sort Ricarda A L Menke
collection DOAJ
description Purpose The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.Participants Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data are currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the leucine-rich repeat kinase 2 or glucocerebrosidase (GBA) genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder-RBD).Findings to date Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’sand RBD. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.Future plans Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.
format Article
id doaj-art-6b7c4018c7df46b485dce3ac2a5f9b1c
institution Kabale University
issn 2044-6055
language English
publishDate 2020-08-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-6b7c4018c7df46b485dce3ac2a5f9b1c2024-12-01T23:00:12ZengBMJ Publishing GroupBMJ Open2044-60552020-08-0110810.1136/bmjopen-2019-034110Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)Ricarda A L Menke0Michael Lawton1Thomas R Barber2Johannes C Klein3Clare Mackay4Konrad Szewczyk-Krolikowski5Michele T Hu6Michal Rolinski7Ludovica Griffanti8Samuel G Evetts9Faye Begeti10Marie Crabbe11Jane Rumbold12Richard Wade-Martins133 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK2Population Health Sciences, University of Bristol3 Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, UK2 Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UKOxford Health, NHS Foundation Trust, Oxford, Oxfordshire, UK1 Neurological and Musculoskeletal Sciences Division, Southmead Hospital, North Bristol NHS Trust, Bristol, UK1 Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UKInstitute of Clinical Neurosciences, University of Bristol, Bristol, UKDepartment of Psychiatry, University of Oxford, Oxford, UKOxford Parkinson’s Disease Centre, University of Oxford, Oxford, UKNeurology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UKOxford Parkinson’s Disease Centre, University of Oxford, Oxford, UKOxford Parkinson’s Disease Centre, University of Oxford, Oxford, UKOxford Parkinson’s Disease Centre, University of Oxford, Oxford, UKPurpose The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.Participants Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data are currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the leucine-rich repeat kinase 2 or glucocerebrosidase (GBA) genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder-RBD).Findings to date Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’sand RBD. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.Future plans Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.https://bmjopen.bmj.com/content/10/8/e034110.full
spellingShingle Ricarda A L Menke
Michael Lawton
Thomas R Barber
Johannes C Klein
Clare Mackay
Konrad Szewczyk-Krolikowski
Michele T Hu
Michal Rolinski
Ludovica Griffanti
Samuel G Evetts
Faye Begeti
Marie Crabbe
Jane Rumbold
Richard Wade-Martins
Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
BMJ Open
title Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_full Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_fullStr Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_full_unstemmed Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_short Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)
title_sort cohort profile the oxford parkinson s disease centre discovery cohort mri substudy opdc mri
url https://bmjopen.bmj.com/content/10/8/e034110.full
work_keys_str_mv AT ricardaalmenke cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT michaellawton cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT thomasrbarber cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT johannescklein cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT claremackay cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT konradszewczykkrolikowski cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT michelethu cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT michalrolinski cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT ludovicagriffanti cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT samuelgevetts cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT fayebegeti cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT mariecrabbe cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT janerumbold cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri
AT richardwademartins cohortprofiletheoxfordparkinsonsdiseasecentrediscoverycohortmrisubstudyopdcmri